This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: M31.1 | Special Copayment Reduction: V135 (rare disease special copayment reduction) |
| B. Synonyms | Thrombotic thrombocytopenic purpura | Thrombotic microangiopathy |
| C. Adult onset | Possible first onset in adulthood: high — acquired TTP mainly occurs in adults in their 30s~50s, and aHUS also commonly occurs in adults. STEC-HUS predominates in children but also occurs in adults. Congenital TTP (Upshaw-Schulman) can manifest in infancy, but milder variants may be first diagnosed in adulthood. |
| 1. History | 1924 Moschcowitz first described TTP → 1955 Gasser described HUS → 1982 Moake discovered vWF ultra-large multimers → 1998 ADAMTS13 identified → 2009 eculizumab approved for aHUS. |
| 2. Causes | TTP: ADAMTS13 deficiency (autoantibody or genetic). HUS: Shiga toxin (Shiga toxin-producing E. coli) or complement dysregulation (aHUS). Others: pregnancy, drugs, HIV. |
| 3. Genetics | TTP: ADAMTS13 gene variants (congenital) + autoantibodies (acquired). aHUS: CFH, CFI, MCP, CFB, C3 variants. Complement gene panel testing is important. |
| 4. General epidemiology | TTP: 3~11 per million per year; women in their 30s~50s. aHUS: 0.2~2 per million per year. STEC-HUS: associated with contaminated meat and vegetables. Occurs worldwide. |
| 5. Pathophysiology | TTP: ADAMTS13 deficiency → UL-vWF accumulation → platelet adhesion and aggregation → microvascular thrombi. HUS: Shiga toxin/complement → endothelial injury → thrombi + platelet consumption. |
| 6. Symptoms | TTP pentad: fever + neurological symptoms + renal failure + thrombocytopenia + microangiopathic hemolytic anemia. HUS triad: thrombocytopenia + acute renal failure + hemolytic anemia. |
| 7. Signs | Peripheral blood smear: schistocytes ≥1%; markedly elevated LDH; direct Coombs negative; ADAMTS13 activity <10% (TTP); bloody stool + E. coli culture (STEC-HUS). Complement panel (aHUS). |
| 8. Screening | For thrombocytopenia + hemolytic anemia of unknown cause, immediate TMA panel (peripheral blood smear, LDH, ADAMTS13, STEC testing, complement). |
| 9. Diagnosis | TMA confirmation: schistocytes + thrombocytopenia + hemolytic anemia. TTP: ADAMTS13 <10%. STEC-HUS: Shiga toxin + bloody diarrhea. aHUS: complement genes + CFH antibody. Differentiation is essential. |
| 10. Treatment | TTP: immediate plasma exchange + steroids + caplacizumab (iTTP). aHUS: eculizumab (anti-C5). STEC-HUS: supportive care (antibiotics contraindicated). |
| 11. Prognosis | TTP: mortality fell to 10~20% after introduction of plasma exchange (90% before treatment). aHUS: renal failure rate at 5 years 50% before eculizumab; improved afterward. Recurrence differs by subtype. |
| 12. Prevention | TTP: rituximab prophylaxis (relapsing). aHUS: eculizumab maintenance + meningococcal vaccine. STEC-HUS: food hygiene (cook raw meat thoroughly). |
| 13. References | 10 major international journals and guidelines |
The history of thrombotic microangiopathy (TMA) begins with the discovery of two major clinical syndromes, thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS).
TTP was first described in 1924 when the New York physician Eli Moschcowitz reported a fatal case of a 16-year-old girl with thrombocytopenia, hemolytic anemia, neurological symptoms, fever, and renal failure occurring together. He described the characteristic pathological finding in this syndrome of widespread thrombus formation in peripheral vessels. At the time, endothelial injury by toxic substances was presumed to be the cause.
HUS was recognized as a separate syndrome in 1955 when the Swiss physician Conrad Gasser and colleagues reported pediatric cases accompanied by the three features of acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia. Later, the association of HUS with Shiga toxin of E. coli O157:H7 was established in 1983 by Karmali and colleagues in Canada, and HUS was divided into diarrhea-associated HUS (D+HUS) and atypical HUS (aHUS).
The decisive breakthrough in TTP pathogenesis came in 1982, when Joel Moake and colleagues discovered unusually large von Willebrand factor multimers (UL-vWF) in the plasma of TTP patients. This suggested a deficiency of the enzyme that cleaves vWF, and in 1998 two independent research groups (Furlan et al., Tsai et al.) identified ADAMTS13, the vWF-cleaving metalloprotease, and proved that this enzyme is severely deficient in TTP patients. In 2001 the ADAMTS13 gene was cloned. With this discovery, TTP was clearly established as a disease caused by ADAMTS13 deficiency. In atypical HUS, variants of complement regulatory proteins (CFH, CFI, MCP, etc.) were identified in the 1990s and 2000s, and in 2009 eculizumab (an anti-C5 monoclonal antibody) received FDA approval as a treatment for aHUS.
Thrombotic microangiopathy (TMA) is not a single disease but a collection of several clinical syndromes that share a common pathology (microvascular thrombi + platelet consumption + microangiopathic hemolytic anemia).
Causes of thrombotic thrombocytopenic purpura (TTP): TTP is caused by severe deficiency of the ADAMTS13 enzyme (activity <10%). ① Acquired TTP (more than 90% of the total): autoantibodies (IgG) against ADAMTS13 inhibit ADAMTS13 activity or promote its renal clearance. This is called immune-mediated TTP (iTTP). ② Congenital (hereditary) TTP (Upshaw-Schulman syndrome): an autosomal recessive disease caused by variants in both alleles of the ADAMTS13 gene (9q34.2).
Causes of hemolytic uremic syndrome (HUS): ① Typical HUS (Shiga toxin-associated, STEC-HUS): Stx1/Stx2 produced by Shiga toxin-producing E. coli (E. coli O157:H7, STEC) bind to the Gb3 receptor on renal endothelial cells and cause inhibition of protein synthesis, endothelial cell death, and complement activation. ② Atypical HUS (aHUS): uncontrolled activation of the complement alternative pathway occurs because of gene variants in complement regulatory proteins (factor H, CFH; factor I, CFI; membrane cofactor protein, MCP/CD46; factor B, CFB; C3) or autoantibodies against CFH.
Other causes of TMA: pregnancy/childbirth-related (gestational TTP, HELLP syndrome, postpartum aHUS), drug-induced (cyclosporine, tacrolimus, mitomycin C, quinine, clopidogrel), infection (HIV, pneumococcus, influenza), malignant hypertension, post-transplant (organ transplantation, hematopoietic stem cell transplantation), autoimmune diseases (lupus, antiphospholipid syndrome), etc.
The genetics of thrombotic microangiopathy (TMA) is best established for TTP (ADAMTS13 gene) and atypical HUS (complement regulatory genes).
Genetics of congenital TTP (Upshaw-Schulman syndrome): the ADAMTS13 gene is located on the long arm of chromosome 9 (9q34.2) and consists of 29 exons. The ADAMTS13 protein consists of 1,427 amino acids and is mainly synthesized in hepatocytes. Congenital TTP occurs when ADAMTS13 activity is severely deficient owing to variants in both alleles (compound heterozygous variants are the most common). More than 200 pathogenic variants have been reported, and they are varied, including point mutations, small deletions, insertions, and splicing variants. The disease is inherited in an autosomal recessive manner, and heterozygous carriers are usually asymptomatic.
Genetics of atypical HUS (aHUS): in about 50~60% of aHUS, complement regulatory gene variants or autoantibodies are identified. ① Factor H (CFH) gene variants: occur in about 25~30% of aHUS; deficiency of a key complement regulatory protein → overactivation of the alternative pathway. ② Membrane cofactor protein (MCP/CD46) gene variants: about 10~15%. ③ Factor I (CFI) gene variants: about 5~10%. ④ Factor B (CFB) gene gain-of-function variants: about 2%. ⑤ C3 gene variants: about 5%. ⑥ THBD (thrombomodulin) gene variants: about 5%. ⑦ Autoantibodies against CFH (anti-CFH): about 5~10% (relatively common in children). These variants show incomplete penetrance, so even in families with the same gene variant only some members develop aHUS.
The epidemiology of thrombotic microangiopathy (TMA) differs greatly by subtype.
Epidemiology of TTP: the annual incidence is reported at about 3~11 per million. By sex, women are affected about 2~3 times more than men, and the median age of onset is in the 30s~50s. It has been reported that the incidence is about 3~7 times higher in Black than in White individuals. Pregnancy-associated TTP accounts for about 12~25% of the total and often appears during pregnancy or after delivery. Recurrence is common in acquired TTP, occurring in about 30~50% after the initial episode.
Epidemiology of aHUS: the annual incidence is about 0.2~2 per million, rarer than TTP. It occurs in both children and adults; in children it is relatively less common than STEC-HUS but accounts for about 5~10% of all pediatric HUS. Adult aHUS was recognized less often than in children, but since the introduction of eculizumab, active diagnosis is also made in adults.
Epidemiology of STEC-HUS: it occurs as a complication of diarrhea after consuming food contaminated with E. coli O157:H7 (undercooked meat, raw vegetables, contaminated water) and occurs mainly in children (especially under 5 years of age). It appears as both sporadic and outbreak forms. It develops in about 5~10% of patients with diarrhea-associated HUS.
Epidemiology in Korea: the number of TMA patients in Korea is not accurately known, but patients registered under code M31.1 (thrombotic microangiopathy) and thrombotic thrombocytopenic purpura are estimated to number in the hundreds under the special copayment reduction V135 criteria.
The pathophysiology of thrombotic microangiopathy (TMA) differs by subtype, but commonly the core pathophysiology is microvascular thrombus formation, platelet consumption, and mechanical destruction of red blood cells.
Pathophysiology of TTP — ADAMTS13 deficiency: normally, ultra-large vWF (UL-vWF) multimers secreted from vascular endothelial cells are immediately cleaved by ADAMTS13 and broken down into normal-sized vWF monomers. When ADAMTS13 is deficient, UL-vWF multimers accumulate on the endothelial cell surface. UL-vWF has a much higher affinity for the platelet GPIb receptor than ordinary vWF, so platelets adhere and aggregate excessively to form platelet-rich thrombi that occlude the microvasculature. These microvascular thrombi form mainly in the brain, kidneys, heart, and adrenal glands, causing ischemic organ damage.
Pathophysiology of STEC-HUS: Stx1/Stx2 bind to the Gb3 (globotriaosylceramide) receptor on the surface of intestinal epithelial cells and renal endothelial cells, enter the cell, and inactivate ribosomes, inhibiting protein synthesis. Destruction of renal endothelial cells causes intravascular thrombus formation, platelet consumption, and red blood cell destruction, producing the three features of HUS. In children, Gb3 is highly expressed on renal endothelial cells, so the kidneys are mainly involved.
Pathophysiology of aHUS: the complement alternative pathway is continuously activated at a low level and is normally suppressed by regulatory proteins such as factor H (CFH), factor I (CFI), and MCP. When regulation becomes insufficient owing to CFH variants and others, complement is activated without control, C3b is excessively deposited on cell surfaces, and the membrane attack complex (MAC, C5b-9) damages endothelial cells. Damaged endothelium becomes the basis for platelet adhesion and aggregation and thrombus formation.
The clinical symptoms of thrombotic microangiopathy (TMA) are divided into common symptoms and subtype-specific symptoms.
Clinical symptoms of TTP: classic TTP was described by a pentad of five features, but only about 5% of cases now satisfy all five, so TTP should be suspected and treatment started on just two features (thrombocytopenia + microangiopathic hemolytic anemia). ① Thrombocytopenia: skin purpura, mucosal bleeding, and rarely severe bleeding. ② Microangiopathic hemolytic anemia (MAHA): fatigue, jaundice, pallor, and appearance of schistocytes. ③ Neurological symptoms: headache, altered consciousness, seizures, stroke, and focal neurological deficits caused by cerebral microvascular thrombi. Fluctuating symptoms are characteristic. ④ Renal dysfunction: mild hematuria, proteinuria, and mild renal function decline. ⑤ Fever.
Clinical symptoms of HUS (STEC-HUS): after ingesting contaminated food, bloody diarrhea begins following an incubation period of 3~7 days. The three features appear within 5~10 days after the onset of diarrhea. ① Thrombocytopenia. ② Microangiopathic hemolytic anemia (fatigue, jaundice, pallor). ③ Acute renal failure (edema, oliguria or anuria, hypertension, symptoms of uremia).
Clinical symptoms of aHUS: an atypical HUS occurring without diarrhea, with more extensive organ involvement than STEC-HUS. Renal involvement is most prominent, and the brain, heart, lungs, gastrointestinal tract, and liver are also involved. The clinical course varies from acute presentation to a chronic relapsing course.
Common symptoms: fatigue, pallor, jaundice (hemolytic anemia), petechiae, purpura, edema, hypertension, oliguria. A sudden, rapidly progressive clinical course is common to all TMAs.
The physical signs and test findings of thrombotic microangiopathy (TMA) are essential for confirming TMA and differentiating its subtypes.
Blood test findings: thrombocytopenia (platelet count <100×10⁹/L, often <30×10⁹/L); markedly elevated LDH (lactate dehydrogenase) — an indicator of hemolysis and tissue damage; elevated total bilirubin (predominantly indirect bilirubin); decreased hemoglobin (hemolytic anemia); decreased or absent haptoglobin; negative direct Coombs test (DAT) — an important distinguishing point from autoimmune hemolytic anemia; increased reticulocytes.
Peripheral blood smear: identification of schistocytes in 1% or more on peripheral blood smear is an essential finding for diagnosing TMA. Schistocytes are fragmented red blood cells formed when red blood cells are mechanically destroyed by microvascular thrombi.
ADAMTS13 testing: to confirm TTP, ADAMTS13 activity (<10% is the criterion for TTP) and ADAMTS13 inhibitor antibodies are measured. The result of this test is key information for deciding treatment (plasma exchange vs. eculizumab).
Renal function indicators: elevated serum creatinine, elevated BUN, increased urea nitrogen, electrolyte abnormalities. Proteinuria and microscopic hematuria on urinalysis.
E. coli testing (STEC-HUS): stool culture and Shiga toxin detection (ELISA or PCR), serum anti-LPS antibodies. Culture of E. coli O157:H7 or detection of Stx in a patient with bloody diarrhea is key to diagnosing STEC-HUS.
Complement testing (aHUS): decreased C3, normal C4 (selective C3 decrease when the alternative pathway is activated), CFH level, complement function tests (CH50, AH50), measurement of CFH autoantibodies.
Thrombotic microangiopathy (TMA) can progress to a life-threatening emergency within days, so immediate diagnostic evaluation is essential when it is clinically suspected.
Indications for immediate evaluation: thrombocytopenia accompanied by microangiopathic hemolytic anemia (direct Coombs-negative hemolysis); sudden altered consciousness + thrombocytopenia; oliguria + thrombocytopenia in a child after bloody diarrhea; thrombocytopenia + hemolysis + renal function decline in a pregnant or postpartum woman.
Tests to perform immediately: complete blood count (check platelet count); peripheral blood smear (check for schistocytes); serum LDH, bilirubin (total, direct, indirect), haptoglobin; direct Coombs test (DAT); serum creatinine, BUN; urinalysis; ADAMTS13 activity and inhibitor antibody testing (to differentiate TTP — blood must be drawn before treatment); stool culture and Shiga toxin detection (if diarrhea is present); complement C3, C4, CFH (if aHUS is suspected); pregnancy test (women of childbearing age).
Urgent importance of ADAMTS13 testing: ADAMTS13 testing is essential for confirming TTP, and when TTP is suspected, plasma exchange must be started immediately even before the results are available. The test result is used to decide the direction of treatment (continuing plasma exchange vs. switching to eculizumab).
Diagnosis of thrombotic microangiopathy (TMA) is divided into a step of confirming TMA and a step of differentiating the causal subtype.
Criteria for confirming TMA: TMA is diagnosed when all three of the following findings are present. ① Thrombocytopenia (platelets <100×10⁹/L or a decrease of >25% from baseline). ② Microangiopathic hemolytic anemia (MAHA): schistocytes (≥1%) on peripheral blood smear, decreased hemoglobin, elevated LDH, decreased haptoglobin, negative direct Coombs test. ③ Organ damage (decreased renal function, neurological abnormalities, gastrointestinal involvement, etc.).
Diagnosis of TTP: confirm ADAMTS13 activity <10%. Immune-mediated TTP (iTTP) is confirmed when ADAMTS13 inhibitor antibodies are positive. Congenital TTP (Upshaw-Schulman) is confirmed when ADAMTS13 gene variants are identified. In TTP, neurological symptoms are often prominent and renal involvement mild.
Diagnosis of STEC-HUS: bloody diarrhea + child under 5 years of age; E. coli O157:H7 culture or Shiga toxin (Stx1/Stx2) positivity in stool. Positive anti-LPS antibodies can also confirm it.
Diagnosis of aHUS: diagnosed after excluding STEC and TTP. Decreased complement C3, decreased CFH level, analysis of the complement gene panel (CFH, CFI, MCP, CFB, C3, THBD), anti-CFH antibodies. aHUS can be diagnosed clinically even without gene variants.
Differential diagnosis: in addition to TTP, STEC-HUS, and aHUS, differentiation is needed from pregnancy complications (HELLP syndrome, gestational hypertension), malignant hypertension, lupus TMA, antiphospholipid syndrome, disseminated intravascular coagulation (DIC), and drug-induced TMA.
Treatment of thrombotic microangiopathy (TMA) differs fundamentally by subtype, so prompt subtype differentiation and immediate treatment are key.
Treatment of TTP: TTP requires emergency treatment, and treatment is started as soon as TTP is suspected without waiting for ADAMTS13 results. ①Plasma exchange (PEX): the first-line standard treatment for TTP, removing ADAMTS13 autoantibodies and supplying normal ADAMTS13. 1~1.5 plasma volumes are exchanged daily with fresh frozen plasma (FFP), continuing until 2 days after normalization of the platelet count and LDH. ②Immunosuppression (steroids): prednisolone (1 mg/kg/day) is used with PEX to suppress autoantibody production. ③Caplacizumab: a nanobody that binds the A1 domain of vWF and blocks the interaction between UL-vWF and platelet GPIb, approved by the EMA in 2018 and the FDA in 2019. The HERCULES clinical trial demonstrated shorter time to TTP remission and reduced recurrence. Triple therapy with PEX + immunosuppression + caplacizumab is the current standard. ④Recurrence prevention: in relapsing iTTP, rituximab eliminates the B cells that produce ADAMTS13 autoantibodies and is effective in preventing recurrence.
Treatment of aHUS: eculizumab (Soliris) and ravulizumab (long-acting) are the standard treatment. These anti-C5 monoclonal antibodies block MAC formation in the complement alternative pathway. Meningococcal vaccination before administration is essential.
Treatment of STEC-HUS: supportive care (fluid replacement, dialysis, transfusion) is the mainstay. Antibiotics can increase Shiga toxin release and worsen progression of HUS, so in principle they are not given.
The prognosis of thrombotic microangiopathy (TMA) varies greatly with the subtype and access to treatment.
Prognosis of TTP: before the introduction of plasma exchange, mortality reached about 85~90%, but with modern treatment (plasma exchange + immunosuppression + caplacizumab) acute-phase mortality has fallen to about 5~15%. Relapses are frequent (about 30~50%), so long-term follow-up is needed. Long-term neurological complications such as cognitive decline, depression, and post-stroke sequelae reduce quality of life. When ADAMTS13 activity remains low even after treatment, rituximab prophylaxis is effective in preventing relapse.
Prognosis of STEC-HUS: with appropriate supportive care, mortality in pediatric STEC-HUS is about 1~5%. Renal function recovers in about 70~80% of patients who needed dialysis in the acute phase. However, in the long term, hypertension, proteinuria, and chronic renal failure persist in about 25~30%.
Prognosis of aHUS: before the introduction of eculizumab, death or end-stage renal failure within 5 years occurred in about 50%. After eculizumab treatment, preservation and recovery of renal function, normalization of platelets, and improved quality of life are reported. Relapse occurs in about 30~40% when eculizumab treatment is stopped, so long-term or indefinite treatment is maintained in most patients.
Prevention of thrombotic microangiopathy (TMA) is approached differently by subtype.
TTP relapse prevention: in patients with relapsing iTTP, administering rituximab to eliminate the B cells that produce ADAMTS13 autoantibodies is effective in preventing relapse. Preemptive rituximab is recommended in patients whose ADAMTS13 activity remains low (at potential risk of relapse). In addition, in pregnancy-related TTP (including congenital TTP), prophylactic plasma infusion during pregnancy is used to prevent relapse.
aHUS relapse prevention: eculizumab treatment is continued or maintained in patients at high risk of relapse. Because the risk of meningococcal (Neisseria meningitidis) infection increases during eculizumab treatment, meningococcal vaccination (MenACWY, MenB) and prophylactic penicillin are essential before starting treatment.
STEC-HUS prevention: food hygiene management is key. Beef (especially ground meat) should be cooked thoroughly through to the center, and raw vegetables and fruits should be washed well. Suspected contaminated water should be boiled before use, and hand hygiene should be strict. Prevention of cross-contamination in group catering facilities is important.
Prevention of pregnancy-related TMA: in pregnant women with a history of TTP or aHUS, prenatal care is managed jointly with rheumatology and hematology specialists, and platelet count and ADAMTS13 activity are monitored regularly during pregnancy.
Patient education: patients are taught to go to the emergency room immediately if signs of TMA recurrence occur, such as sudden bruising or petechiae, jaundice, extreme fatigue, headache or altered consciousness, and decreased urine output.
Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries. Arch Intern Med. 1925;36:89-93.
Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87(10):4223-4234. PMID: 8639781.
Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323-335. DOI: 10.1111/j.1365-2141.2012.09167.x.
Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681-696. DOI: 10.1016/S0140-6736(17)30062-4.
Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(6):511-522. DOI: 10.1056/NEJMoa1505533.
Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169-2181. DOI: 10.1056/NEJMoa1208981.
Coppo P, Bussel A, Charrier S, et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/haemolytic-uraemic syndrome. Medicine (Baltimore). 2003;82(1):27-38.
Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844-1859.
Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis. 1985;151(5):775-782. PMID: 3886804.
Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307(23):1432-1435. PMID: 6813748.